Bayer’s adjusted EBITDA was 2. 51 billion euros in the third quarter, beating consensus of 2.307 billion euros. DAX Group now expects a full-year turnover of 50.5-51.5 billion euros (previously 50-51 billion euros). Adjusted profit per share is estimated at EUR 7.70. DZ Bank analysts consider 7.99 euros possible (previously: 7. 6 euros). In their new research, they confirm a buy recommendation on Bayer shares. The target price drops from EUR 76.00 to EUR 75.00. Inflation will negatively affect costs both in the last quarter and in 2023. In the pharmaceutical industry, this transition for customers is likely to be limited. Analysts believe that the amount of glyphosate reserves (8 billion euros) should be enough. , shares of Bayer (WKN: BAY001, ISIN: DE000BAY0017, Kaavio) are almost unchanged at €55. 5.